Robert C. Doebele, MD, PhD | Authors

Articles

Evaluating Next Steps for Entrectinib in ROS1-Positive NSCLC

January 18, 2020

Robert C. Doebele, MD, PhD, shares his thoughts on what the next steps are for entrectinib in patients with ROS1-positive non–small cell lung cancer. In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are ROS1-positive.

The Significance of Results for Entrectinib in ROS1+ NSCLC

October 24, 2017

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non–small cell lung cancer (NSCLC).